RBC: Neos Therapeutics Has 70% Upside, $500 Million Opportunity

RBC Capital Markets analyst Randall Stanicky initiated Neos Therapeutics Inc NEOS at an Outperform with a $35 price target – 70 percent above Friday's $20.63 closing price.

Stanicky pointed to "bullish feedback from our physician survey" that suggests that the three late-stage treatments for ADHD could drive $500 million in peak sales. Neos' ADHD treatments are either orally disintegrating tablets (ODT) or liquid suspension treatments, which should serve ADHD's large pediatric/adolescent population well, RBC said. In fact, in RBC's physician survey, nearly half of physicians said that an ODT would be their "No. 1 treatment preference if available."

The first treatment could be approved as early as November 9, the note said. This gives the stock a near-term catalyst that could propel it higher. At the same time, FDA approval – if it happened – would further validate Neos' ODT and liquid suspension technologies. Beyond ADHD, RBC said that Neos should have the opportunity to apply those technologies more broadly with a potential new pipeline announced by year-end.

On the downside, RBC said that a bearish scenario could see the price could slip to $8. Risks to the $35 price target are regulatory risks given the company's late-stage products, increased generic competition, and litigation risks.

Since its IPO in mid-July, Neos has gained 5.6 percent. The company hit a high of $23.99 and a low of $17.10 during this time.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorBiotechInitiationAnalyst RatingsGeneralNeos TherapeuticsRandall StanickyRBC Capital Markets
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!